HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib
HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1, -2, and -3, for the treatment of refractory metastatic colorectal cancer.
"This FDA submission is a significant milestone for patients in the United States who have metastatic CRC, one of the most common and deadly cancers in the United States and around the world." In China, where it has been available since 2018, fruquintinib is an important tre...
